All In Biotech

Drug Trial Radar · NCT05708235

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

A Proof of Concept Study to Evaluate Treatments' Efficacy by Monitoring Minimal Residual Disease Using ctDNA in HR-positive/HER2-negative Early Breast Cancer Population

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

976

Planned (sponsor's estimate)

Start

Apr 1, 2024

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
MedSIRAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a multicenter, open-label, non-comparative, phase II, biomarker-driven adjuvant treatment study involving the periodic collection and analysis of blood samples from patients with HR-positive/HER2-negative early-stage BC at higher risk of relapse, who have undergone surgery within the previous five years, with no evidence of locoregional, contralateral, or distant disease. The study design is composed by an initial pre-screening phase, a molecular follow-up phase (ctDNA surveillance phase), and an interventional therapeutic phase (treatment phase). After informed consent is obtained, a total of 976 eligible patients will enter a ctDNA surveillance in which primary tumor tissue and matched normal blood will be collected from each patient to obtain a patient-specific somatic mutations panel (tumor signature). At the event of ctDNA positivity, patients will be screened to enter the treatment phase of the study. Upon confirmed eligibility, a total of 40 patients will be allocated in one of the following trial's arms adopting a sequential recruitment strategy: Arm A: Control Arm (N=10) Arm B: Experimental Arm with giredestrant (N=10) Arm C: Experimental Arm with giredestrant + abemaciclib (N=10) Arm D: Experimental Arm with giredestrant + inavolisib (N=10) If the strategy of ctDNA monitoring enables physicians to identify patients at high risk of relapse and assess whether treatment at molecular relapse can improve outcome, new cohorts may be added to the study.

Conditions

  • Breast Cancer

Interventions

  • GiredestrantDrug

    Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)

  • AbemaciclibDrug

    Abemaciclib is an orally administered CDK4/6 inhibitor

  • InavolisibDrug

    Inavolisib is a potent, selective inhibitor of the Class I phosphatidylinositol 3-kinase α (PI3K-alpha isoform (p110-alpha)

  • Standard ET followed by change in treatmentDrug

    90-day period of standard ET in accordance with standard clinical practice, followed by one of the other three predefined treatments (giredestrant, giredestrant plus abemaciclib or giredestrant plus inavolisib if a detectable PIK3CA mutation is present and the participant also meets all additional eligibility criteria for Arm D).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of decrease or clearance in baseline ctDNA at three months after initiation of study treatmentTime frame: Treatment phase (three months after Study treatment initiation)

Locations

41 sites in 2 countries. Site status is shown where the registry gives one.

  • Complejo Hospitalario Universitario A Coruña (CHUAC)

    A Coruña, Spain

  • Hospital General Universitario Dr. Balmis

    Alicante, Spain

  • Hospital Marina Salud de Denia

    Alicante, Spain

  • Hospital Virgen de los Lirios

    Alicante, Spain

  • Fundació Althaia

    Barcelona, Spain

  • Hospital Clínic i Provincial de Barcelona

    Barcelona, Spain

  • Hospital Universitari Dexeus

    Barcelona, Spain

  • Hospital Universitario de Basurto

    Bilbao, Spain

  • Hospital Provincial de Castellón

    Castellon, Spain

  • Hospital Universitario Reina Sofía

    Córdoba, Spain

  • Hospital del Vinalopó

    Elche, Spain

  • Institut Català d' Oncologia Girona (ICO)

    Girona, Spain

  • Hospital Universitario Clínico San Cecilio de Granada

    Granada, Spain

  • Complejo Hospitalario de Jaén

    Jaén, Spain

  • Hospital Universitario de León

    León, Spain

  • Hospital Universitario Arnau de Vilanova de Lleida

    Lleida, Spain

  • Clínica Universidad de Navarra

    Madrid, Spain

  • Hospital Beata María Ana

    Madrid, Spain

  • Hospital Universitario de Torrejón

    Madrid, Spain

  • Hospital Universitario Doce de Octubre

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario Sanchinarro-START-CIOCC

    Madrid, Spain

  • Hospital Regional Universitario de Málaga (Hospital Carlos Haya)

    Málaga, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain

  • Hospital Clínico Universitario Virgen de la Arrixaca

    Murcia, Spain

  • Hospitalario Universitario de Navarra

    Pamplona, Spain

  • Hospital de Sagunto

    Sagunto, Spain

  • Hospital Quirónsalud Sagrado Corazón

    Seville, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Spain

  • Hospital Universitari Sant Joan de Reus

    Tarragona, Spain

  • Hospital Arnau de Vilanova de Valencia

    Valencia, Spain

  • Hospital Clínico Universitario de Valencia

    Valencia, Spain

  • Hospital Universitari i Politècnic La Fe

    Valencia, Spain

  • Hospital Universitario La Ribera, Alzira

    Valencia, Spain

  • Complejo Hospitalario Universitario de Vigo

    Vigo, Spain

  • Hospital de Xativa

    Xàtiva, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain

  • University Hospital Coventry

    Coventry, United Kingdom

  • Royal Surrey County Hospital NHS Foundation Trust

    Guildford, United Kingdom

  • Barts Cancer Institute

    London, United Kingdom

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.